一种细胞因子修饰的同种异体全细胞胰腺癌疫苗的研发。
Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.
作者信息
Laheru Dan, Biedrzycki Barbara, Jaffee Elizabeth M
机构信息
The Sidney Kimmel Cancer Center, the Skip Viragh Clinical Pancreatic Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
出版信息
Methods Mol Biol. 2013;980:175-203. doi: 10.1007/978-1-62703-287-2_9.
Management of patients with pancreatic cancer is a multidisciplinary approach that presents enormous challenges to the clinician. Overall 5-year survival for all patients remains <3%. Symptoms of early pancreas cancer are nonspecific. As such, only a fraction of patients are candidates for surgery. While surgical resection provides the only curative option, most patients will develop tumor recurrence and die of their disease. To date, the clinical benefits of chemotherapy and radiation therapy have been important but have led to modest improvements. Tumor vaccines have the potential to specifically target the needle of pancreas cancer cells amidst the haystack of normal tissue. The discovery of pancreas tumor-specific antigens and the subsequent ability to harness this technology has become an area of intense interest for tumor immunologists and clinicians alike. Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer.
胰腺癌患者的管理是一种多学科方法，给临床医生带来了巨大挑战。所有患者的总体5年生存率仍低于3%。早期胰腺癌的症状不具有特异性。因此，只有一小部分患者适合手术。虽然手术切除是唯一的治愈选择，但大多数患者会出现肿瘤复发并死于该疾病。迄今为止，化疗和放疗的临床益处虽很重要，但改善程度有限。肿瘤疫苗有可能在正常组织的“干草堆”中特异性地靶向胰腺癌细胞这根“针”。胰腺肿瘤特异性抗原的发现以及随后利用该技术的能力，已成为肿瘤免疫学家和临床医生都极为感兴趣的领域。在不了解特定抗原靶点的情况下，整个肿瘤细胞是免疫抗原的最佳来源。本章将重点探讨胰腺癌全肿瘤细胞疫苗策略的发展。
Zotero 插件